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Abstract
Background: Gene-environment interactions are likely to explain some of the heterogeneity in childhood asthma.
Here, we describe the methodology and experiences in establishing a database for childhood asthma designed to
study gene-environment interactions (PAGES - Paediatric Asthma Gene Environment Study).
Methods: Children with asthma and under the care of a respiratory paediatrician are being recruited from 15
hospitals between 2008 and 2011. An asthma questionnaire is completed and returned by post. At a routine clinic
visit saliva is collected for DNA extraction. Detailed phenotyping in a proportion of children includes spirometry,
bronchodilator response (BDR), skin prick reactivity, exhaled nitric oxide and salivary cotinine. Dietary and quality of
life questionnaires are completed. Data are entered onto a purpose-built database.
Results: To date 1045 children have been invited to participate and data collected in 501 (48%). The mean age
(SD) of participants is 8.6 (3.9) years, 57% male. DNA has been collected in 436 children. Spirometry has been
obtained in 172 children, mean % predicted (SD) FEV1 97% (15) and median (IQR) BDR is 5% (2, 9). There were
differences in age, socioeconomic status, severity and %FEV1 between the different centres (p≤0.024). Reasons for
non-participation included parents not having time to take part, children not attending clinics and, in a small
proportion, refusal to take part.
Conclusions: It is feasible to establish a national database to study gene-environment interactions within an
asthmatic paediatric population; there are barriers to participation and some different characteristics in individuals
recruited from different centres. Recruitment to our study continues and is anticipated to extend current
understanding of asthma heterogeneity.
Background
Asthma is a common condition diagnosed in as many as
2 5 %o fS c o t t i s hc h i l d r e nb yt h ea g eo f1 1y e a r s [ 1 ] .
Childhood asthma is heterogeneous in terms of severity
[2], natural history [2] and response to treatment[3] and
mechanisms for the disease heterogeneity among chil-
dren with asthma is not well-understood but genetic
and environment factors and, crucially, combinations
thereof are thought to be relevant.
Asthma heterogeneity is most commonly classified by
severity. Several genetic variations have been associated
with asthma severity in children, including those within
genes coding for filaggrin [4], macrophage inhibitory
factor [5], interleukin-4 [6] and the beta 2 adrenoceptor
[7]. Additionally, regulatory genes for ORMDL3 [8] and
IL12B [9] have been associated with asthma severity.
Environmental exposures have also been associated with
asthma severity and include tobacco smoke[10] and
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increased asthma severity in association with obesity[12]
and reduced dietary antioxidants[13]. Whilst gene-envir-
onment interactions are described for asthma causation
in children [14,15] there is also the potential for such
interactions to explain why asthma severity varies within
a population[16]. A proof-of-concept study[17] found
that children with more severe asthma were more likely
to carry at least one G allele for the CD14 gene but this
is seen only among those exposed to tobacco smoke.
Large databases, for example BioBank UK http://www.
ukbiobank.ac.uk and the Avon Longitudinal Study of Par-
ents and Children (ALSPAC), have the potential to study
gene-environment interactions in the context of asthma
causation. However, understanding the relevance of
gene-environment interactions to asthma heterogeneity
will require a relatively large study population of children
with asthma to provide enough statistical power to
observe common interactions with a small effect and less
frequent interactions which have a greater effect. Follow-
ing a successful pilot of the methodology in Aberdeen,
we have commenced recruiting patients under the care
of consultant paediatricians with a special interest in
asthma across Scotland. The aims of the Paediatric
Asthma Gene Environment Study (PAGES) are:
1. To recruit children with asthma attending second-
ary care clinics
2. To ascertain the children’se n v i r o n m e n t a l
exposures.
3. To obtain saliva samples consented for DNA pre-
paration and genetic analysis.
4. To create a dataset sufficient to elucidate hypoth-
esis-driven gene-environment interactions using a nested
case-control design.
Initial gene-environment interactions of primary interest
are between (i) exposure to tobacco smoke and dietary
oxidants and genetic variations of the Glutathione
S-transferase (GST) gene family and (ii) exposure to
tobacco smoke and variations in the gene coding for filag-
grin. With the advent of rapidly advancing technologies
and the reduction in sequencing costs, we aim to combine
the present population with the BREATHE cohort [4,18]
and apply whole genome technologies to a population
which is expected to number in excess of 2500 children
and young adults with asthma.
The aims of the present report are to describe the meth-
odology, demonstrate the feasibility of recruitment,
describe our experience in establishing the database and
report the characteristics of the children initially recruited.
Methods
Study design
This is a cross-sectional study of asthmatic children
attending hospital clinics across Scotland (figure 1) and
Brighton, England (included as a validation centre). An
asthma questionnaire is completed and returned by
post. Children are invited to attend a clinical assessment
that includes: spirometry, bronchodilator response, skin
prick reactivity, exhaled nitric oxide measurement and
saliva collection for cotinine assay and DNA extraction.
Dietary and quality of life questionnaires are also com-
pleted during or after the clinical assessment A sample
of saliva for DNA analysis can be collected by parents
and returned by post in cases when clinical attendance
is refused.
Researchers
Researchers are based in five centres: Aberdeen (recruit-
ing in Aberdeen, Inverness, Elgin, Perth and Dundee),
Edinburgh (Edinburgh, Kirkcaldy, Melrose and Stirling),
Glasgow (Glasgow, Wishaw and Paisley), Kilmarnock
(Kilmarnock, Paisley and Dumfries) and Brighton.
Researchers dispatch questionnaires, collect DNA and
undertake the assessments in accordance with standard
operating procedures and using identical apparatus.
Eligibility criteria
Asthma is defined as a recurrent wheezing condition
diagnosed as asthma by a consultant paediatrician who is
a member of the Scottish Paediatric Respiratory Interest
Group. All asthmatic children aged 2-16 years attending
a clinic between March 2008 and November 2011 will be
eligible. Exclusion criteria include children with coexist-
ing respiratory morbidity, for example cystic fibrosis,
bronchopulmonary dysplasia (BPD), and the following
significant non-respiratory problems, cerebral palsy,
Down’s syndrome, gastro-oesophageal reflux (prescribed
medications) and marked developmental delay. Children
born prematurely but who did not have BPD are eligible;
premature delivery is noted in the questionnaire.
Enrolment
Our pilot study indicated that recruitment will not
exceed 60% and therefore the gender, age and postcode
of all children invited to participate are recorded to
demonstrate how representative participants are of all
the children invited to enroll. A deprivation index is
derived from the postcode using 2009 Scottish Index of
Multiple Deprivation data[19] (SIMD). Written consent
is obtained from the parent when the asthma question-
naire is completed and verbal assent from the child at
the time of the clinical assessment. This study has been
approved by the Cornwall and Plymouth Research
Ethics Committee
Questionnaires
The asthma questionnaire (available at http://www.
asthma-pages.com/participants/what/) included the
Turner et al. BMC Medical Research Methodology 2010, 10:107
http://www.biomedcentral.com/1471-2288/10/107
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[6], questions relating to asthma control (the Child
Asthma Control Test®, used with permission) and envir-
onmental exposures (from Biobank). The Paediatric
Asthma Quality of Life Questionnaire [7] and food fre-
quency questionnaires (Scottish Collaborative Group
semi-quantitative food frequency questionnaire version
C1 http://www.foodfrequency.org) were also completed
by parents.
Clinical assessment
The assessment took place in conjunction with a sched-
uled clinic appointment or at a dedicated research clinic.
The detailed assessment included (in this order) exhaled
nitric oxide (FENO), spirometry, skin prick reactivity and
bronchodilator response. The assessment of children
aged under 5 years included only skin prick reactivity
since FENO and reliable spirometry are often not
obtained in this younger age group[20,21].
Exhaled NO
Exhaled NO is measured using a portable NO analyser
(NIOX MINO®, Aerocrine, Solna Sweden) in accordance
with international recommendations[22]. Measurements
from this device have been validated against a gold stan-
dard[20] and can be obtained in >90% in those aged
over 7 years[20].
Spirometry and bronchodilator response
These are measured in accordance with standard guide-
lines[23] using a portable spirometer (ML3500, Micro-
Lab), calibrated before each assessment. Values are
expressed as percentage of predicted according to nor-
mative data[24]. The bronchodilator response is defined
as the change in FEV1 15 minutes after inhalation of
200 micrograms salbutamol, delivered from a pres-
surised metered dose inhaler via large volume spacer
device (Volumatic®, GlaxoSmithKline, UK). Parents and
children are asked to withhold short acting beta agonists
Figure 1 A map of Scotland identifying the recruitment centres. 1 = Inverness, 2 = Elgin, 3 = Aberdeen, 4 = Dundee, 5 = Perth, 6 = Stirling,
7 = Kirkcaldy, 8 = Paisley, 9/10 = Glasgow, 11 = Wishaw, 12 = Edinburgh, 13 = Kilmarnock, 14 = Melrose, 15 = Dumfries.
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for 12 hours.
Skin prick reactivity
The standard methodology[25] is used to determine skin
prick reactivity to eight common environmental aller-
gens including: Dermatophagoides pteronyssinus, cat
dander, dog dander, whole egg, Alternaria alternans,
Aspergillus fumigatus, peanut and grass (ALK, North-
ampton). The positive control is histamine 10 mg/ml
and the negative control 0.9% saline. A positive skin test
is defined as a weal ≥3 mm in longest diameter or, in
cases of dermatographism, greater than the negative
control. Testing is withheld in individuals who have
taken anti histamines within the previous 72 hours.
Testing for peanut is withheld in children with a history
of peanut anaphylaxis. Children with a positive reaction
to peanut but no history of reaction after ingestion of
peanuts are offered referral for peanut challenge.
DNA collection, storage and analysis
Oragene sampling kits (DNA Genotek Inc, Ottowa,
Canada), were used to obtain DNA from a saliva speci-
men. Five swabs (DNA Genotek Inc, Ottowa, Canada)
are used to collect saliva for DNA analysis in young
children who cannot actively provide a saliva sample.
Saliva is either obtained by the researcher during a hos-
pital visit or occasionally by the parent at home and
then mailed to the researcher. Saliva samples are imme-
diately labeled using preprinted barcode labels which are
also attached to the case report form. This provides an
immediate and robust de-identification system to retain
the privacy of the study subjects, but retaining the abil-
ity to link genotype to phenotype within the study.
Salivary Cotinine
Saliva is collected for cotinine assay using a sterile
absorbent cotton wool swab (Salivette®, Sarstedt Ltd,
Leicester, UK) which is placed between teeth and buccal
mucosal for three minutes before being inserted into a
plastic case. Specimens are spun down and saliva frozen
for analysis by ELISA (ABS laboratories, Welywn Gar-
den City, UK). Cotinine exposure is analysed as a con-
tinuous variable and values of ≥15 ng/ml assumed to
indicate active smoking by the child. Values below the
limit of detection (0.1 ng/ml) are assigned a value of
0.05 ng/ml.
Establishment and population of the database
T h ee x p e r i e n c eg a i n e df r o me stablishing and validating
the UK CF database[26] has been applied to the PAGES
database. The database is currently a stand alone (non-
networked) system (figure 2). There is the option for
future remote, web based access to the database now
that the fields are fully agreed and the methodology is
stable. The advantage of using a database system for
development (rather than working with a spreadsheet or
statistics package) is that database systems naturally
facilitate the inclusion and preparation for the analysis
of longitudinal data. Standard validation checks have
been incorporated as described in detail elsewhere
[26,27] and include restricted fields, e.g. age is a numeric
field between 2 and 16, gender is a categorical field
either “male” or “female”.
Quality control
To ensure a standardised methodology all researchers
work to the same standard operating procedure and use
identical equipment. Researchers have a certificate from
Association for Respiratory Technology and Physiology/
British Thoracic Society; this is a national qualification
for those practitioners who complete the Spirometry
assessment. All researchers attend a monthly minuted
teleconference where methodological issues that arise
are discussed and resolved. Finally, all data are entered
onto one central database by an individual. All queries
or errors identified at the verification stage are notified
back to the researcher within 2 weeks of receipt; this
approach is proven to result in data entry of high qual-
ity[26]. An audit of data is undertaken in the course of
the present analysis.
Power calculation
Power calculations are based on the pilot study. The sam-
ple size needed to detect the interaction of a genetic factor
with an exposure depends on the prevalence of exposure
and genotype, the relative risk for exposure and genotype
alone, magnitude of the gene-environment interaction, the
case-control ratio and the type I and type II error [28]. For
example to explore the relationship between tobacco
smoke exposure (assuming 50% prevalence) and GSTT
null genotype (assuming 50% prevalence) and the presence
of atopic illness as an outcome among an asthmatic popu-
lation, assuming relative risks of interaction (Ri) of 2 and
5, studies including 414 and 103 non-atopic asthmatics
respectively will have power of 80% to detect an interac-
tion at 5% level of significance [29]. To relate an interac-
tion between filaggrin variants (assuming 10% prevalence)
and second hand smoke exposure (assuming 50% preva-
lence) with asthma severity, assuming relative risks of
interaction of 2 and 5, studies including 199 and 105 asth-
matics on British Thoracic Society (BTS) treatment steps
4 and 5 respectively will have power of 80% at 5% level of
significance[29].
Statistical approach to analyzing the final dataset
Statistical analysis will be conducted using logistic
regression which permits adjustment for confounders,
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To test for gene-environmental interaction, an interaction
variable will be created based on the combination of fac-
tors investigated[30]. First the model will be fitted with
both variables as separate term, then with an interaction
term. The statistical significance of the interaction will be
obtained from likelihood ratio test of change in deviance
between the second model and the first.
Statistical approach to present report
Differences between centres were compared using chi
square, Mann Whitney-U test and Kruskal Wallis test as
appropriate. Significance is assumed at p = 0.05. Stan-
dard statistical software is used (SPSS version 17.0.0)
Results
Recruitment
At the time of writing 1045 children have been invited
to participate (figure 3), of whom a DNA sample has
been obtained in 436 (42%) and asthma questionnaire in
382 (37%); the discrepancy in numbers where DNA and
questionnaire were obtained is in part explained by
many of the latter currently being entered onto the
database. Recruitment has been underway for more than
12 months in seven centres (listed in table 1), for more
than six months in nine centres and for more than one
month in fourteen centres. An audit of the database
found several discrepancies between treatment and
BTS/SIGN treatment step; the error is not at the level
of data entry rather at the level of the researcher coding
the treatment step. The audit found no outliers and
other than BTS/SIGN step, data were ready for analysis.
Reasons for non-participation
These were prospectively ascertained as part of the pilot
study where 91 children were invited to participate of
whom 57 (62%) were enrolled. Of the 34 children who
were not enrolled, the parents of 17 did not have time
to participate during the clinic visit, 10 did not attend
the scheduled clinic appointment, five refused to take
part and two children did not have asthma. When the
centres recruiting for less than a year were combined
Figure 2 A view of one of the screens on the database.
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ied between 38% and 72%, p = 0.004, table 1.
Factors associated with participation
For the purpose of the present study, participation is
defined as at least a DNA sample or asthma question-
naire being obtained (n = 501). The mean age (standard
deviation) of those enrolled is 8.6 (3.9) years and 9.2 (4.0)
years for those who did not enroll (T test p = 0.022).
There were 288 boys recruited (57% of all enrolled)
and 359 boys (64%) among those who did not enroll
(c
2
1 = 4.71, p = 0.030). The median (range) SIMD decile
was the same (6 (1, 10)) for those who did and did not
enroll (Mann Whitney U test p = 0.135).
Figure 3 A Consort diagram demonstrating the number of individuals where data are available. Recruitment is ongoing and these
numbers will increase before the end of the study.
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These details are presented in table 1. The centres
where recruitment has been under way for less than a
year were combined to form an eighth group. There
were significant inter-centre differences in the age of
children invited to take part (p = 0.002), SIMD (p <
0.001), BTS treatment step (p = 0.002), % predicted
FEV1 (p = 0.024) but not gender or FENO.
Participant details
The mean age (SD) was 8.6 years (3.9) and 57% were
boys. There were 118 children aged under five years
including 24 aged between two and three years and 55
aged three to four years. The proportions of children on
each British Thoracic Society treatment step were: 29%
step 2, 60% step 3, 10% step 4 and 1% step 5. Saliva was
collected for DNA analysis in 436 and for cotinine assay
in 225. Spirometry was measured in 172 children, mean
(SD) % predicted FEV1,F V Ca n dF E F 25-75 were 97%
(15), 106% (13) and 79% (27) respectively. Bronchodila-
tor response was measured in 154 children and the
median (interquartile range) was 5% (2, 9). Exhaled NO
was measured in 185, median (IQR) value 18 (12, 50)
parts per billion. Skin prick reactivity was measured in
120 children including 99 who were reactive. Reasons
for missing pulmonary function data include young age,
refusal to provide measurements and inability to provide
measurements of adequate quality. Reasons for missing
skin prick reactivity data include recent receipt of
antihistamines, previous peanut anaphylaxis and refusal
to have testing. There were no significant associations
between BTS treatment step (severity) and physiological
outcomes including spirometry, BDR or FENO.
Salivary cotinine validation of tobacco smoke exposure
Salivary cotinine concentration was determined in 139
children and was in excess of 15 ng/ml in six individuals
(median age 14.5 years). The median (SEM) cotinine for
children with no resident smokers was 0.5 ng/ml (0.04),
with one resident smoker was 0.58 ng/ml (0.16) and
with two resident smokers was 1.39 (0.95), Kruskal Wal-
lace test p < 0.001.
Different administrative requirements between centres
Although the study is categorised site-specific exempt by
the ethics committee, three centres still requested Site
Specific Assessment documents. One centre requested a
materials transfer agreement with the host university.
Some centres, but not all, required visiting researchers
to have honorary contracts. In some centres, approval
documents are sent initially to Research and Develop-
ment departments whereas in others these documents
go directly to the local Research Ethics Committee.
Discussion
Here we describe the methodology and feasibility for
recruiting children with asthma on a national basis. To
our knowledge this is the first study specifically designed
Table 1 Comparison of participation rates, ages and asthma outcomes between centres
Centre Number of children Mean age (years) Median SIMD decile Mean %
FEV1
Median FENO
(SEM), ppb
Median BTS
treatment step
Invited Participated Participants Non
participants
Participants Non
participants
Aberdeen 167 93 8.8 (4.1) 9.1 (4.3) 7 7 96 (17) 27 (6) 3
n=4 1 n=4 1
Dundee 220 91 8.1 (4.2) 9.0 (4.4) 6 5 100 (17) 25 (6) 3
n=4 5 n=4 4
Edinburgh 271 140 8.5 (4.1) 9.8 (4.3) 7 5 91 (11) 16 (4) 3
n=3 8 n=5 4
Elgin 70 29 8.9 (4.1) 9.8 (4.3) 6.5 5 103 (12) 17 (6) 3
n=1 2 n=9
Kirkcaldy 80 42 6.8 (3.3) 8.5 (3.6) 5 4 93 (14) 11 (18) 3
n=9 n=8
Melrose 24 17 11.1 (3.0) 10.5 (3.8) 7 5 93 (9) 14 (7) 3
n=1 3 n=1 5
Perth 119 45 10.0 (3.4) 9.8 (3.7) 6 7 104 (12) 41 (10) 3
n=1 4 n=1 4
Other 94 64 9.0 (4.3) 8.3 (4.3) 4 4 none None 2.5
Overall 1045 501 8.6 (3.9) 9.2 (4.0)* 6 † 6 97 (15)† 18 (2) 3 (2, 3)†
SIMD = Scottish Index of Multiple Deprivation, SEM = Standard Error of Mean, BTS = British Thoracic Society.*p = 0.022 for comparison between participants and
non participants. † p value for trend tests for %FEV1, SIMD decile and BTS severity between centres <0.05.
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asthma causation which has been the focus of much
research interest. In addition to describing our metho-
dology, we provide novel findings including barriers to
participation in asthma research, details of passive
smoke exposure in children with asthma and differences
in the characteristics of children with asthma recruited
from centres across the nation. These experiences may
be relevant to colleagues interested establishing national
and international single-disease databases in other
countries.
The potential for national single-disease databases to
study respiratory disease has already been demonstrated
in cystic fibrosis. Cystic fibrosis (CF) databases have
been established in several countries including the UK
[31] and have lead to a better understanding of disease
heterogeneity [32,33] and also added to our understand-
ing of genetic mechanisms[34]. Asthma is more preva-
lent than CF and an asthma diagnosis is made on a
solely clinical basis but notwithstanding these important
differences between asthma and CF, we believe that the
known benefits of national CF databases will be applic-
able to the present asthma database.
We are not aware of pre-existing large single-disease
asthma databases from which the relationship between
asthma heterogeneity and gene-environment interactions
can be studied, but cross-sectional and longitudinal stu-
dies of asthmatic populations in Europe [18,35], United
States[36] and Australia[2] have provided important
insights into the heterogeneity of the natural history of
asthma. A number of publications from the Childhood
Asthma Management Programme[36] (a randomised-
controlled trial including 1041 asthmatic children with
follow up for over four years) have demonstrated asso-
ciations between genetic variations and heterogeneity in
response to asthma treatment [37-39]. A study of the
5244 asthmatic children who took part in the whole-
population NHANES III survey in the US also found
evidence for asthma heterogeneity in terms of both risk
factors and severity [40]. These studies[2,18,35-40] give
some insight into the heterogeneity of childhood asthma
and the present study seeks to explore the variability
described.
One challenge to our study is the absence of gold
standard for measuring asthma heterogeneity outcomes.
Severity is most commonly outcome used and in adult
populations, indices of asthma severity have been devel-
oped and validated for use in large databases[41]. Based
on our prior experiences [4,18] we will use BTS treat-
ment step as our primary heterogeneity outcome. Once
the dataset is complete we will explore the utility of
other severity outcomes, for example asthma control,
FEV1,F E NO, hospitalisations and the number of courses
of oral steroids over the past year. Additionally, we will
explore heterogeneities in treatment response, i.e.
bronchodilator response, and symptom triggers in the
context of plausible gene-environment interactions.
Our methodology has a number of strengths, weak-
nesses and limitations. A key strength is that we have
demonstrated that our methodology captures a hetero-
geneous population in terms of severity, as evidenced by
BTS treatment, skin prick reactivity, exhaled nitric oxide
and spirometry. A second strength is that phenotyping
is carried out by researchers who use standardised
methodology in all centres; this approach to quality con-
trol minimises the risk of heterogeneity arising between
centres due to methodological differences. A third
strength is that we have validated second hand smoke
exposure, one of our principle exposures of interest,
with a biomarker. A weakness of the study is the low
recruitment rate, which at present is less than 50% and,
as evidenced by our pilot study, is not expected to
exceed 60%. We have described the barriers to participa-
tion and these are not previously described in the con-
text of asthma and include pressure on parent’st i m e
but uncommonly outright refusal to participate. An
intervention study of behaviour problems in children
has also reported time demands explaining 50% of non-
participation[42]. Despite this relatively low recruitment
rate, our study is likely to be adequately powered; for
example we have already recruited more than half of the
105 children on BTS treatment steps 4 and 5 required
to explore interactions between filaggrin gene variants
and ETS. A second weakness is that spirometry, exhaled
NO and skin prick reactivity data have not been
obtained in individuals where exposure and genetic date
are available; reasons for non-collection of clinical data
include young children not being able to provide spiro-
metry and exhaled NO data and skin reactivity data
missing in those with peanut anaphylaxis. One limita-
tion to this study is its cross sectional nature and we
will seek funding to follow up those recruited to study
disease remission and persistence over time. We
acknowledge that the present study is hospital-based
and the results may not be relevant to all children with
asthma in the community. A further potential limitation
to the study is inclusion of children as young as two
years since asthma and viral induced wheeze are preva-
lent in preschool children and distinguishing between
the two conditions can be difficult. The proportion of
preschool children with recurrent wheeze is greater than
in older children [43] but in the present study, pre-
school children were in the minority which might sug-
gests that our inclusion criteria may be excluding
children with non-asthmatic preschool wheeze; in our
final analysis we will consider the whole dataset and
then exclude the preschool group to address this
limitation.
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Page 8 of 11Assessment of environmental exposures is not without
difficulties in such studies as this. Our methodology
includes salivary cotinine as an objective index of expo-
sure to second hand tobacco smoke (SHS) and we have
observed higher exposure among those with greater
reported exposure. The concentrations of salivary coti-
nine are lower than those in an earlier study undertaken
in Dundee [44] where the average concentration in asth-
matic children where two adults smoked is 4.02 ng/ml
and 1.62 ng/ml where only mother smoked. This appar-
ent fall in salivary cotinine concentrations may represent
a genuine reduction in exposure of asthmatic children to
SHS between 1994 and the present time or may be due
to parents in the present study reducing their child’s
exposure to SHS prior to the assessment knowing that
cotinine is to be measured. Questionnaire information
on factors such as smoking, parental smoking, use of
gas fires and gas hobs and open fires is usually reason-
ably robust and memory of past exposures by the par-
ents will be reasonable as the time scale is relatively
short in comparison with studies of historical exposures
in adults. The child’s home address will provide the abil-
ity to model outdoor air pollution exposure and future
secondary studies could directly assess of indoor air
quality, for example concentrations of particulate matter
(PM10 and PM2.5) ,r e l e v a n tg a s e s( n o t a b l yo x i d e so f
nitrogen) and volatile organic compounds. Exposure to
other factors such as chemicals in the home known to
be associated with respiratory symptoms[45] is less clear
cut but the development of this database would allow
additional studies to be added to the core concept
(much as has been done in ALSPAC[45]) to allow speci-
fic issues to be addressed with more specific measure-
ment of any relevant environmental exposures.
In summary, our study aims to provide a dataset from
which to explore the influence of gene-environment
interactions in childhood asthma. The gene-environment
interactions associated with asthma causation will not
necessarily explain asthma heterogeneity and we hope to
report novel insights into genetic variations within an
asthmatic population. Although the primary purpose of
the study is to further understanding of asthma hetero-
geneity, there are other potential applications of the pre-
sent study and these are listed in table 2.
Conclusions
We conclude that it is feasible to study gene environ-
ment interactions in children with asthma by recruiting
from multiple centres. There are differences in partici-
pation rates and patient characteristics between centres.
The main reasons for non-participation in such a study
were lack of time on parent’s behalf and failure to
attend clinic appointments.
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